Merck & Co (MRK) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Apr, 2026Voting matters and shareholder proposals
Election of 13 directors is up for vote, with all nominees recommended by the board.
Advisory vote on executive compensation (say-on-pay) is included.
Ratification of the independent registered public accounting firm for 2026 is proposed.
Shareholder proposals include reports on DEI risks in federal contracting, healthcare coverage gaps, and political contributions; board recommends voting against these.
Board of directors and corporate governance
Board recommends all 13 director nominees for election at the annual meeting.
Executive compensation and say-on-pay
Non-binding advisory vote on the compensation of named executive officers is on the agenda.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Merck & Co
- Pipeline momentum and innovation are driving accelerated growth and de-risking.MRK
Goldman Sachs 47th Annual Global Healthcare Conference 20269 Jun 2026 - Phase III data and strategic partnerships drive innovation in oncology and CML pipelines.MRK
Jefferies Global Healthcare Conference 20264 Jun 2026 - KEYTRUDA and novel assets drive robust oncology growth, with $25B+ pipeline potential and durable efficacy.MRK
Investor update2 Jun 2026 - 2025 results showed growth, pipeline expansion, and all board nominees approved; shareholder proposals failed.MRK
AGM 202627 May 2026 - Q1 2026 sales up 5% to $16.3B, but a $9B Cidara charge led to a net loss; guidance raised.MRK
Q1 20264 May 2026 - 2025 saw robust growth, pipeline expansion, and strong governance, with a focus on sustainability.MRK
Proxy filing8 Apr 2026 - $6.7B deal adds TERN-701, a next-gen CML therapy, to drive hematology and oncology growth.MRK
M&A announcement8 Apr 2026 - Transforming to a diversified, innovation-driven portfolio with robust late-stage pipeline assets.MRK
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Oncology and animal health drove 7% sales growth, offsetting GARDASIL China declines.MRK
Q4 20243 Feb 2026